Sensorion Receives Approval to Commence P-I/II Study of SENS-501 (OTOF-GT) for Hearing Impairment Across European Countries
Shots:
- Sensorion has received approval for its Clinical Trial Application (CTA) to commence a P-I/II study of SENS-501 (OTOF-GT), based on preclinical studies to evaluate the safety and efficacy, in France
- The P-I/II (Audiogene) study will assess the safety, tolerability, and efficacy of SENS-501 for treating OTOF gene-mediated hearing impairment in pediatric patients 6-31mos. of age. Information about the first patient is anticipated in H2’24
- SENS-501 (OTOF-GT) dual vector AAV gene therapy is developed to restore hearing in individuals with mutations in the gene coding for otoferlin protein who have severe to profound sensorineural prelingual non-syndromic hearing loss
Ref: Sensorion | Image: Sensorion
Related News:- Sensorion’s SENS-401 Receives Australia’s Approval for the Initiation of Proof-of-Concept Trial to Treat Hearing Impairment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
